Sun Yat-sen University
中山大学
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 555 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 85
- Research papers it led
- 555
- Trials it led
- 243
- Share of China's trials
- 40.8%
- Share of the world's papers
- 17.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 stu
- Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.
- Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial.
- Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.
- Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial.
Trials on ClinicalTrials.gov6
- Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
- Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
- GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
- Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
- A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 179 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 15
- Research papers it led
- 179
- Trials it led
- 48
- Share of China's trials
- 8.5%
- Share of the world's papers
- 4.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
- Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
- Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trial.
- Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.
Trials on ClinicalTrials.gov6
- Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
- An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
- Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
- Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer
Hepatocellular carcinoma
肝细胞癌Led 820 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 52
- Research papers it led
- 820
- Trials it led
- 232
- Share of China's trials
- 15.8%
- Share of the world's papers
- 2.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.
- Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial.
- Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.
- Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.
- Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Trials on ClinicalTrials.gov6
- Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
- Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
- Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
- TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
- SBRT Versus Surgical Resection for Small HCC
Stomach cancer
胃癌Led 283 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 14
- Research papers it led
- 283
- Trials it led
- 61
- Share of China's trials
- 4.2%
- Share of the world's papers
- 1.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
- Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
- Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.
Trials on ClinicalTrials.gov6
- Large Language Models Assist in Tumor MDT
- Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
- Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
- Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
- Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
Hepatoblastoma
肝母细胞瘤Led 9 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.6%).
- Open trials led
- 1
- Research papers it led
- 9
- Trials it led
- 2
- Share of China's trials
- 20.0%
- Share of the world's papers
- 2.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Prognostic factors and treatment outcomes of hepatoblastoma in children: a SEER database analysis.
- The importance of age as a prognostic predictor of childhood hepatoblastoma: an analysis of single-center childhood hepatoblastoma in China.
- Computed tomography imaging phenotypes of hepatoblastoma identified from radiomics signatures are associated with the efficacy of neoadjuvant chemotherapy.
- Treatment optimization for recurrent hepatoblastoma: retrospective study from a hepatoblastoma cohort in Southern China.
- Two-stage laparoscopic resection of giant hepatoblastoma in infants combined with liver partial partition and artery ligation.
Trials on ClinicalTrials.gov2
- A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
- Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
Retinoblastoma
视网膜母细胞瘤Led 28 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 1
- Research papers it led
- 28
- Trials it led
- 7
- Share of China's trials
- 53.8%
- Share of the world's papers
- 2.5%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial.
- EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target.
- Polyester 5-0 suture for porous implant placement after retinoblastoma enucleation: analysis of 120 sockets.
- RNA Sequencing and Bioinformatic Analysis on Retinoblastoma Revealing that Cell Cycle Deregulation Is a Key Process in Retinoblastoma Tumorigenesis.
- Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening.
Trials on ClinicalTrials.gov6
- Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
- Topotecan and Melphalan for Retinoblastoma
- Efficacy Study of Lucentis in the Treatment of Retinoblastoma
- Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation
- Attention to Retinoblastoma Diagnosed in the Trauma Setting
- Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study
Osteosarcoma
骨肉瘤Led 75 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 1
- Research papers it led
- 75
- Trials it led
- 5
- Share of China's trials
- 8.6%
- Share of the world's papers
- 1.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Multiomics integration analysis identifies tumor cell-derived MIF as a therapeutic target and potentiates anti-PD-1 therapy in osteosarcoma.
- Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes.
- A prediction model of pulmonary metastasis risk in pediatric patients with stage IIB osteosarcoma in the long bone of extremities.
- Lenvatinib Monotherapy Versus Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Osteosarcoma: A Real-World Study.
- Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.
Trials on ClinicalTrials.gov6
- Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
- Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
- Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
- Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma
Gastrointestinal stromal tumour
胃肠道间质瘤Led 20 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 2
- Research papers it led
- 20
- Trials it led
- 6
- Share of China's trials
- 8.1%
- Share of the world's papers
- 1.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research.
- Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study.
- Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
- CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
Trials on ClinicalTrials.gov6
- A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
- Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study of Olverembatinib in SDH-deficient GIST.
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTs
Neuroblastoma
神经母细胞瘤Led 16 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 6
- Research papers it led
- 16
- Trials it led
- 9
- Share of China's trials
- 21.4%
- Share of the world's papers
- 0.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach.
- Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial.
- SLIT3-mediated intratumoral crosstalk induces neuroblastoma differentiation via a spontaneous regression-like program.
- Mechanism of Drug Resistance to First-Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas.
- SUV39H1 epigenetically modulates the MCPIP1-AURKA signaling axis to enhance neuroblastoma tumorigenesis.
Trials on ClinicalTrials.gov6
- Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
- Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
- Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
- Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
- Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
- Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
Ewing sarcoma
尤文肉瘤Led 6 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 1
- Research papers it led
- 6
- Trials it led
- 2
- Share of China's trials
- 12.5%
- Share of the world's papers
- 0.5%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Adamantinoma-like ewing sarcoma arising in the pancreatic tail: a case report of a rare entity and review of the literature.
- Long-term follow-up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities.
- SETD8 inhibits apoptosis and ferroptosis of Ewing's sarcoma through YBX1/RAC3 axis.
- AURKA inhibition induces Ewing's sarcoma apoptosis and ferroptosis through NPM1/YAP1 axis.
- KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis.
Multiple myeloma
多发性骨髓瘤Led 49 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 0
- Research papers it led
- 49
- Trials it led
- 6
- Share of China's trials
- 1.2%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
- Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.
- Structural and functional characterization of multiple myeloma associated cytoplasmic poly(A) polymerase FAM46C.
- Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma.
- Evolving treatments and outcomes in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a real-world study in China.
Trials on ClinicalTrials.gov6
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
B-cell acute lymphoblastic leukaemia (B-ALL)
B 细胞急性淋巴细胞白血病Led 10 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.9%).
- Open trials led
- 1
- Research papers it led
- 10
- Trials it led
- 2
- Share of China's trials
- 0.8%
- Share of the world's papers
- 0.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Dysregulated arginine metabolism in precursor B-cell acute lymphoblastic leukemia in children: a metabolomic study.
- Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.
- The potential role of RNA sequencing in diagnosing unexplained insensitivity to conventional chemotherapy in pediatric patients with B-cell acute lymphoblastic leukemia.
- Case Report: CD19 and CD20 monoclonal antibodies with sequential chemotherapy for refractory acute B-lymphocytic leukemia in children.
- Evaluation of diagnostic efficacy of NRP-1/CD304 in hematological diseases.
Trials on ClinicalTrials.gov6
- Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Study of YK012 in B-cell Acute Lymphoblastic Leukemia
- Monitoring Minimal Residual Disease(MRD)in Pediatric B-acute Lymphoblastic Leukemia
- A Study of Ponsegromab in People With Heart Failure
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Aplastic anaemia
再生障碍性贫血Led 3 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Diagnosis and treatment of Diamond-Blackfan anemia and Pierre-Robin sequence caused by a novel mutation of RPS28 gene.
- Evaluating the causal role of circulating inflammatory cytokines and plasma metabolites on aplastic anemia.
- Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
Haemophagocytic lymphohistiocytosis (HLH)
噬血细胞性淋巴组织细胞增生症Led 9 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.3%).
- Open trials led
- 0
- Research papers it led
- 9
- Trials it led
- 1
- Share of China's trials
- 2.1%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Predictive value of routine laboratory tests for early death in pediatric hemophagocytic lymphohistiocytosis patients.
- Prognostic scoring model incorporating clinical characteristics for pediatric hemophagocytic lymphohistiocytosis: a multicenter retrospective study.
- Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis.
- Treatment of pediatric refractory or relapsed Epstein-Barr virus-associated hemophagocytic syndrome with PD-1 inhibitors.
- The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Trials on ClinicalTrials.gov2
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Beta thalassaemia
β 地中海贫血Led 14 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.9%).
- Open trials led
- 0
- Research papers it led
- 14
- Trials it led
- 2
- Share of China's trials
- 4.3%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Identification of a Patient with Transfusion-Dependent β-Thalassemia Caused by Compound Heterozygous Mutations of HBB: C.84_85insC and Common Linked Intronic Variants in HBB.
- Clinical patterns of thalidomide in the treatment of transfusion-dependent β-thalassaemia in children: a prospective single-arm study in China.
- A Chinese pediatric patient with thalassemia traits and compound heterozygous mutations in the PIEZO1 gene suspected of having dehydrated hereditary stomatocytosis.
- A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent β-thalassemia.
- Technically feasible solutions to challenges in preimplantation genetic testing for thalassemia: experiences of multiple centers between 2019 and 2022.
Trials on ClinicalTrials.gov5
- A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
- The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study
- Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
Haemophilia A
血友病 ALed 3 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (15.8%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Recent Advances in Gene Therapy for Hemophilia.
- A Response to: Letter to the Editor Regarding "Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China".
- Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China.
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 46 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 3
- Research papers it led
- 46
- Trials it led
- 4
- Share of China's trials
- 5.1%
- Share of the world's papers
- 2.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder.
- Choroidal structure differs between multiple sclerosis and neuromyelitis optica spectrum disorder: An enhanced depth imaging optical coherence tomography study.
- Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4-IgG-positive neuromyelitis optica spectrum disorder during acute attacks.
- Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.
- Impact of Treatment Delay and Prognostic Factors in Acute Myelitis of Neuromyelitis Optica Spectrum Disease.
Trials on ClinicalTrials.gov6
- Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
- Cohort Study on Neuroimmune Diseases in the Reproductive Age
- Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders
- A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
IgG4-related disease
IgG4相关性疾病Led 6 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.1%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- The Diagnostic and Follow-Up Value of Contrast-Enhanced Ultrasound of IgG4-Associated Hepatic Inflammatory Pseudotumor: A Case Report and Review.
- Clinicopathological characteristics of IgG4-related lung disease.
- Inflammatory pseudotumor of Castleman disease and IgG4-related disease masquerading as kidney malignancy.
- IgG4-related disease with nasopharyngeal malignancy-like manifestations.
- The function of IL-33/ST2 signaling axis in treg cells activating fibrosis in IgG4-related disease.
Myasthenia gravis
重症肌无力Led 28 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 1
- Research papers it led
- 28
- Trials it led
- 4
- Share of China's trials
- 4.3%
- Share of the world's papers
- 1.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Preoperative respiratory muscle training combined with aerobic exercise improves respiratory vital capacity and daily life activity following surgical treatment for myasthenia gravis.
- Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.
- Multiple concurrent opportunistic infections in patient with myasthenia gravis: A case report.
- Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center study.
- Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neonatal intensive care unit.
Trials on ClinicalTrials.gov6
- Cohort Study on Neuroimmune Diseases in the Reproductive Age
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- Myasthenia Gravis Registry in China
- Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
- Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia Gravis
- The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
Moyamoya disease
烟雾病Led 7 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- RNF213 loss-of-function promotes pathological angiogenesis in moyamoya disease via the Hippo pathway.
- Treatment Options for Patients With Moyamoya Disease: A Retrospective Cohort Study.
- Exploration of the risk factor for infarction after revascularization in moyamoya disease.
- Longitudinal evaluation of cerebral perfusion evolution after revascularization surgery in moyamoya disease by CT perfusion.
- Persistent trigeminal artery in a patient with moyamoya disease:a case report and literature review.
Wilson disease
肝豆状核变性(Wilson 病)Led 7 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.5%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 1
- Share of China's trials
- 6.2%
- Share of the world's papers
- 1.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Bilateral Blurry Vision After a Liver Transplant.
- Metal deposits associated with brain atrophy in the deep gray matter nucleus in Wilson's disease.
- Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.
- Symptom aggravation after withdrawal of metal chelating agent therapy in patients with Wilson's disease.
- Plasma neurofilament light chain as a biomarker in Wilson's disease.
Trials on ClinicalTrials.gov1
Biliary atresia
胆道闭锁Led 13 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.8%).
- Open trials led
- 0
- Research papers it led
- 13
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Interpretable artificial intelligence-based app assists inexperienced radiologists in diagnosing biliary atresia from sonographic gallbladder images.
- Gamma-Glutamyl Transferase Combined With Conventional Ultrasound Features in Diagnosing Biliary Atresia: A Two-Center Retrospective Analysis.
- Postnatal outcomes of fetuses with isolated gallbladder anomalies: be aware of biliary atresia.
- Ultrasound characteristics combined with gamma-glutamyl transpeptidase for diagnosis of biliary atresia in infants less than 30 days.
- The combination of conventional ultrasound and shear-wave elastography in evaluating the segmental heterogeneity of liver fibrosis in biliary atresia patients after Kasai portoenterostomy.
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 24 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 24
- Trials it led
- 1
- Share of China's trials
- 16.7%
- Share of the world's papers
- 3.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Overlapping autoimmune encephalitis with tripartite autoantibody positivity (NMDAR, GFAP, mGluR5) associated with papillary thyroid carcinoma: a case report.
- Machine Learning and Shapley Additive Explanations Value Integration for Predicting the Prognostic of Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Model Development and Evaluation Study.
- Safety and Efficacy of a Neonatal Fc Receptor Antagonist in Patients With Anti-NMDAR Encephalitis.
- Clinical and Brain MRI Characteristics of Patients with Anti-N-Methyl-<sc>d</sc>-Aspartate Receptor Encephalitis: A 10-Year Retrospective Study.
- Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks.
Trials on ClinicalTrials.gov1
Takayasu arteritis
大动脉炎Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (24.6%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Trials on ClinicalTrials.gov1
Hepatic echinococcosis
肝包虫病Led 3 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (32.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 1
- Share of China's trials
- 50.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Deep learning diagnosis of hepatic echinococcosis based on dual-modality plain CT and ultrasound images: a large-scale, multicenter, diagnostic study.
- Perioperative outcomes and hospitalization costs of radical vs. conservative surgery for hepatic cystic echinococcosis: A retrospective study.
- Recent advances in ultrasound in the diagnosis and evaluation of the activity of hepatic alveolar echinococcosis.
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 17 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 17
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Acute fibrinous and organizing pfneumonia: two case reports and literature review.
- ACSL4 Drives C5a/C5aR1-Calcium-Induced Fibroblast-to-Myofibroblast Transition in a Bleomycin-Induced Mouse Model of Pulmonary Fibrosis.
- Refined Murine Model of Idiopathic Pulmonary Fibrosis.
- High matrix stiffness promotes senescence of type II alveolar epithelial cells by lysosomal degradation of lamin A/C in pulmonary fibrosis.
- A novel mouse model of pulmonary fibrosis: twice-repeated oropharyngeal bleomycin administration mimicking human pathology.
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 10 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- MPO/HOCl Facilitates Apoptosis and Ferroptosis in the SOD1G93A Motor Neuron of Amyotrophic Lateral Sclerosis.
- Prognostic factors affecting ALS progression through disease tollgates.
- Inferring the genetic relationship between brain imaging-derived phenotypes and risk of complex diseases by Mendelian randomization and genome-wide colocalization.
- NRF2 activation suppresses motor neuron ferroptosis induced by the SOD1G93A mutation and exerts neuroprotection in amyotrophic lateral sclerosis.
- Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes.
Spinal muscular atrophy
脊髓性肌萎缩症Led 4 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (29.1%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Reduced white matter integrity and disrupted brain network in children with type 2 and 3 spinal muscular atrophy.
- Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
- Cardiac function evaluation in children with spinal muscular atrophy: A case-control study.
- Disrupted individual-level morphological brain network in spinal muscular atrophy types 2 and 3.
Trials on ClinicalTrials.gov2
Duchenne muscular dystrophy
杜氏肌营养不良Led 7 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.8%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Discordant Monozygotic Triplets with Duchenne Muscular Dystrophy.
- Serum creatinine as a biomarker for dystrophinopathy: a cross-sectional and longitudinal study.
- A rare case of monozygotic triplets with Duchenne muscular dystrophy.
- Deficient Astrocyte Homeostatic Support Contributes to Brain Impairment in Duchenne Muscular Dystrophy.
- Cardiac CIP protein regulates dystrophic cardiomyopathy.
Behçet disease
白塞病Led 13 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 0
- Research papers it led
- 13
- Trials it led
- 1
- Share of China's trials
- 5.9%
- Share of the world's papers
- 1.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Novel loss-of-function intronic mutation in ELF4 is associated with intestinal autoinflammation.
- Predicting Factors of Long-term Outcome of Gastrointestinal Behçet's Disease: A Chinese Retrospective Study.
- Successful Remission with Upadacitinib in Two Patients with Anti-TNF-Refractory Macular Edema Associated with Behçet's Uveitis.
- Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis.
- Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis.
IgA nephropathy
IgA 肾病Led 36 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 2
- Research papers it led
- 36
- Trials it led
- 8
- Share of China's trials
- 6.8%
- Share of the world's papers
- 2.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study.
- Left ventricular remodeling in IgA nephropathy: Prognostic implications and clinical correlations.
- Renal survival and improvement in younger malignant hypertension patients with thrombotic microangiopathy.
- Clinicopathological Characteristics and Prognosis of IgA Nephropathy Combined With Malignant Hypertension Kidney Injury.
- Retrospective analysis of glucocorticoid therapy in pediatric immunoglobulin A nephropathy: Kidney outcomes and efficacy.
Trials on ClinicalTrials.gov6
- IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
- IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
- A Study of SHR-2173 in Participants With Primary IgA Nephropathy
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Correlation of Microbiome and Metabonomics With IgA Nephropathy
- Steroids Therapy in IgA Nephropathy With Crescents
Primary biliary cholangitis
原发性胆汁性胆管炎Led 3 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 2
- Share of China's trials
- 4.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- The effects of lifestyle factors on primary biliary cholangitis ascertained by two-sample Mendelian randomization.
- Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia.
- Comprehensive analysis of immune signatures in primary biliary cholangitis and autoimmune hepatitis.
Trials on ClinicalTrials.gov6
- FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Probiotics in PBC Patients of Poor Response to UDCA
- Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.0%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Hirschsprung disease
先天性巨结肠Led 2 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.0%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 3 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (21.1%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Clinical and genetic landscape of optic atrophy in 826 families: insights from 50 nuclear genes.
- Variant and clinical landscape of Leber hereditary optic neuropathy based on 1516 families with mtDNA variants in a tertiary centre.
- Non-Pharmaceutical Interventions against COVID-19 Causing a Lower Trend in Age of LHON Onset.